ISM8207 for advanced solid tumors and B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, ISM8207, for people with advanced solid tumors or certain B-cell lymphomas that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have an advanced solid tumor that has worsened after standard treatment, or a B-cell lymphoma that has come back or stopped responding to treatment.
- You are able to perform daily activities without significant help (ECOG score 0 or 1).
- You have not taken certain other drugs in the last 28 days or 5 half-lives (whichever is shorter).
- You agree to use effective birth control during the study and for 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests an experimental drug called ICP-B794 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and begins to show signs of shrinking tumors.
This study tests a new drug (BMS-986482) alone or with other treatments for people with advanced solid tumors that haven't responded to standard therapies. The goal is to see if this drug can shrink tumors or slow their growth.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
This study tests a new drug (SYS6005) that targets a protein called ROR1 on certain cancer cells. It is for people with advanced solid tumors or B-cell lymphomas that have stopped responding to other treatments.
This trial tests a new oral drug called ISM5939 for people with advanced solid tumors that haven't responded to or can't use standard treatments. The goal is to see if the drug is safe and works against the cancer.
This trial tests an experimental drug called IBD0333 for people with advanced solid tumors or lymphoma who have run out of standard options. The drug targets a protein called 4-1BB to help your immune system fight cancer.
Hear when a new Relapsed/Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.